| P02CA03 |
Albendazole |
ZENTEL |
Tablet |
400 |
mg |
1 |
ГлаксоСмитКлайн ЕООД, България |
400 |
mg |
3.05 |
- |
3.05 |
3.05 |
100% |
3.05 |
за лечение на ехинококоза. Ограничение: За експертиза по чл.78 т.2 от ЗЗО |
B67.0,B67.1,B67.3,B67.5,B67.6 |
№ 190/ 22.08.2011; КЦРР-2590/14.03.2013 г; НСР-3391/29.04.2014; НСР-6677/09.07.2015 |
02.11.2019 |
08.09.2012 |
16.11.2013 |
Активен |
2784 |
| R03AC02; R03CC02 |
Salbutamol |
R03AC02; R03CC02 Salbutamol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AC02 |
Salbutamol |
BUTO-ASMA |
Pressurised inhalation, suspension |
0,1 mg/dose - 200 doses |
mg |
1 |
Чайкафарма Висококачествените лекарства АД, България |
0.8 |
mg |
5.92 |
- |
0.144 |
3.6 |
100% |
3.6 |
|
J44.8,J45.0,J45.1 |
НСР-18347/05.04.2019 |
02.05.2019 |
08.09.2012 |
|
Активен |
564 |
| R03AC02 |
Salbutamol |
Ecosal Easi-Breathe |
Pressurised inhalation, suspension |
0,1 mg/dose - 200 doses |
mg |
1 |
Teva Czech Industries s.r.o., Чешка република |
0.8 |
mg |
6.5 |
- |
0.1528 |
3.82 |
100% |
3.82 |
|
J44.8,J45.0,J45.1 |
№ 121/ 09.12.2010; КЦРР-1199/13.08.2012 г.; НСР-70/07.06.2013; НСР-2631/03.02.2014; НСР-5962/01.04.2015.; НСР-12237/03.04.2017 |
02.05.2017 |
08.09.2012 |
|
Заличен |
3785 |
| R03AC02 |
Salbutamol |
Ecosal Inhaler |
Pressurised inhalation, suspension |
0,1 mg/dose - 200 doses |
mg |
1 |
Teva B.V., Нидерландия |
0.8 |
mg |
5.9 |
- |
0.144 |
3.6 |
100% |
3.6 |
|
J44.8,J45.0,J45.1 |
№ 121/ 09.12.2010; НСР-17173/09.11.2018 |
02.12.2018 |
08.09.2012 |
|
Активен |
663 |
| R03AC02 |
Salbutamol |
SALBUTAMOL INHALER |
Pressurised inhalation, suspension |
100 mcg/metered actuation - 200 doses |
mg |
1 |
GlaxoSmithKline (Ireland) Limited, Ирландия |
0.8 |
mg |
3.6 |
- |
0.144 |
3.6 |
100% |
3.6 |
|
J44.8,J45.0,J45.1 |
№ 101/ 20.09.2010; КЦРР-2665/20.03.2013 г.; НСР-2429/21.01.2014; НСР-12563/05.05.2017; НСР-15953/22.06.2018; НСР-18242/22.03.2019 |
02.05.2019 |
08.09.2012 |
|
Активен |
2452 |
| R03CC02 |
Salbutamol |
Salbutamol Sandoz |
Pressurised inhalation, suspension |
100 mcg/dose - 200 doses |
mg |
1 |
Sandoz d.d., Словения |
0.8 |
mg |
3.71 |
- |
0.144 |
3.6 |
100% |
3.6 |
|
J44.8,J45.0,J45.1 |
НСР-1636/11.11.2013; НСР-11770/17.02.2017; НСР-18772/21.05.2019 |
02.07.2019 |
|
|
Активен |
2246 |
| R03AC12 |
Salmeterol xinafoate |
R03AC12 Salmeterol xinafoate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AC12 |
Salmeterol |
Serevent inhaler |
Pressurised inhalation, suspension |
25 mcg/dose x 120 doses |
mg |
1 |
ГлаксоСмитКлайн ЕООД, България |
0.1 |
mg |
20.64 |
- |
0.688 |
20.64 |
100% |
20.64 |
|
J44.8,J45.0,J45.1 |
КЦРР-1203/13.08.2012 г.; HCР-273/28.06.2013; НСР-3201/07.04.2014; НСР-5209/04.12.2014; НСР-10028/18.08.2016; НСР-10954/17.11.2016 |
02.01.2017 |
08.09.2012 |
|
Заличен |
3433 |
| R03AC18 |
Indacaterol |
R03AC18 Indacaterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AC18 |
Indacaterol |
Onbrez Breezhaler |
Inhalation powder, hard capsule |
150 (120 mcg/delivered dose) |
mcg |
30 capsules (1 caps. 120 mcg/delivered dose) + 1 inhaler |
Novartis Europharm Limited, Ирландия |
1 |
caps |
- |
57.58 |
1.91933 |
57.58 |
75% |
43.18 |
|
J44.8 |
№ 192/ 23.08.2011; НСР-1441/10.10.2013; НСР-3673/06.06.2014; НСР-4179/23.07.2014; НСР-5545/29.01.2015; НСР-9221/ 05.05.2016; НСР-11553/26.01.2017 г.; Протокол 231/29.06.2017; Протокол 244/28.09.2017; НСР-14237/19.10.2017; НСР-16109/13.07.2018; НСР-16313/27.07.2018; НСР-18096/07.03.2019 |
02.04.2019 |
08.09.2012 |
|
Активен |
3546 |
| R03AC19 |
Olodaterol |
R03AC19 Olodaterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AC19 |
Olodaterol |
Striverdi Respimat |
Inhalation solution |
2,5 |
mcg |
1 respimat inhaler and 1 cartridge (60 doses) |
Boehringer Ingelheim International GmbH, Германия |
5 |
mcg |
- |
59.14 |
1.97133 |
59.14 |
75% |
44.36 |
|
J44.8 |
НСР-7563/24.11.2015; НСР-14917/25.01.2018 |
02.03.2018 |
|
|
Заличен |
4113 |
| R03AK06 |
Salmeterol xinafoate/ Fluticasone propionate |
R03AK06 Salmeterol xinafoate/ Fluticasone propionate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AK06 |
Salmeterol, Fluticasone |
Aerivio Spiromax |
Inhalation powder |
50 mcg/500 mcg |
|
1 inhaler (60 doses) |
Teva B.V., Нидерландия |
2 |
UD |
64.54 |
- |
1.418 |
42.54 |
100% |
42.54 |
|
J44.8,J45.0,J45.1 |
НСР-12270/07.04.2017; НСР-15920/15.06.2018; НСР-18913/06.06.2019 |
02.07.2019 |
|
|
Заличен |
15649 |
| R03AK06 |
Salmeterol, Fluticasone |
AirFluSal Forspiro |
Inhalation powder, pre dispensed |
50 mcg/250 mcg/dose - 60 doses |
UD |
1 |
Sandoz d.d., Словения |
2 |
UD |
33.31 |
- |
1.11033 |
33.31 |
100% |
33.31 |
|
J45.0,J45.1 |
НСР-6895/06.08.2015; НСР-9202/05.05.2016; НСР-13499/18.08.2017; КП-39/15.04.2019 и НСР-17268/14.11.2018 |
02.06.2019 |
|
|
Активен |
4060 |
| R03AK06 |
Salmeterol, Fluticasone |
AirFluSal Forspiro |
Inhalation powder, pre dispensed |
50 mcg/500 mcg/ dose-60 doses |
UD |
1 |
Sandoz Pharmaceuticals d.d., Словения |
2 |
UD |
42.54 |
- |
1.418 |
42.54 |
100% |
42.54 |
|
J44.8,J45.0,J45.1 |
НСР-4246/30.07.2014.; НСР-7270/21.10.2015.; КП-33/25.05.2017 и НСР-11769/17.02.2017; НСР-16860/21.09.2018 предварително изпълнение |
02.10.2018 |
|
|
Активен |
3051 |
| R03AK06 |
Salmeterol, Fluticasone |
Salmeterol and fluticasone Cipla |
Pressurised inhalation, suspension |
25 mcg/250 mcg |
|
120 doses |
Cipla Europe NV, Белгия |
2 |
UD |
43.93 |
- |
0.73217 |
43.93 |
100% |
43.93 |
|
J45.0,J45.1 |
НСР-15801/08.06.2018; корекционно решение НСР-16098/05.07.2018; НСР-19751/04.09.2019 |
02.10.2019 |
|
|
Активен |
16271 |
| R03AK06 |
Salmeterol, Fluticasone |
Salmeterol and fluticasone Cipla |
Pressurised inhalation, suspension |
25 mcg/125 mcg |
|
120 doses |
Cipla Europe NV, Белгия |
2 |
UD |
35.4 |
- |
0.59 |
35.4 |
100% |
35.4 |
|
J45.0,J45.1 |
НСР-15801/08.06.2018; корекционно решение НСР-16098/05.07.2018; НСР-19751/04.09.2019 |
02.10.2019 |
|
|
Активен |
16272 |
| R03AK06 |
Salmeterol, Fluticasone |
SERETIDE DISCUS |
Inhalation powder, pre dispensed |
50 mcg/100 mcg/dose - 60 doses |
UD |
1 |
ГлаксоСмитКлайн ЕООД, България |
2 |
UD |
37.51 |
- |
1.25033 |
37.51 |
100% |
37.51 |
|
J45.0,J45.1 |
№26/04.08.2009; № 67/ 08.04.2010; №37/21,08,2009; НСР-2703/06.02.2014; КП-189/30.04.2015; НСР-6182/08.05.2015; НСР-9233/05.05.2016; НСР-10022/18.08.2016; НСР-14513/23.11.2017; НСР-17834/30.01.2019; НСР-19867/27.09.2019 |
02.11.2019 |
08.09.2012 |
|
Активен |
3879 |
| R03AK06 |
Salmeterol, Fluticasone |
SERETIDE DISCUS |
Inhalation powder, pre dispensed |
50 mcg/250 mcg/dose - 60 doses |
UD |
1 |
ГлаксоСмитКлайн ЕООД, България |
2 |
UD |
51.67 |
- |
1.11033 |
33.31 |
100% |
33.31 |
|
J45.0,J45.1 |
№26/04.08.2009; № 67/ 08.04.2010; №37/21,08,2009; НСР-2643/03.02.2014; НСР-4904/22.10.2014; НСР-6675/09.07.2015; НСР-9233/05.05.2016; НСР-10437/29.09.2016; НСР-14681/20.12.2017; НСР-18283/28.03.2019 |
02.06.2019 |
08.09.2012 |
|
Активен |
3331 |
| R03AK06 |
Salmeterol, Fluticasone |
SERETIDE DISCUS |
Inhalation powder, pre dispensed |
50 mcg/500 mcg/dose - 60 doses |
UD |
1 |
ГлаксоСмитКлайн ЕООД, България |
2 |
UD |
64.54 |
- |
1.418 |
42.54 |
100% |
42.54 |
|
J44.8,J45.0,J45.1 |
№26/04.08.2009; № 67/ 08.04.2010; №37/21,08,2009; НСР-4601/15.09.2014; НСР-10990/24.11.2016; НСР-15079/23.02.2018 |
02.10.2018 |
08.09.2012 |
|
Активен |
3205 |
| R03AK07 |
Budesonide/Formoterol |
R03AK07 Budesonide/Formoterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AK07 |
Budesonide, Formoterol |
AIRBUFO FORSPIRO |
Inhalation powder, pre dispensed |
160 mcg + 4,5 mcg/dose 60 doses |
UD |
2 |
Sandoz Pharmaceuticals d.d., Словения |
4 |
UD |
46.93 |
- |
1.56433 |
46.93 |
100% |
46.93 |
|
J44.8,J45.0,J45.1 |
НСР-19247/18.07.2019; НСР-19373/26.07.2019-Предварително изпълнение |
02.08.2019 |
|
|
Активен |
16618 |
| R03AK07 |
Budesonide, Formoterol |
DuoResp® Spiromax® |
Inhalation powder |
320 mcg/9 mcg/dose - 60 doses |
UD |
1 |
Teva Pharma B.V., Нидерландия |
2 |
UD |
60.19 |
- |
1.56433 |
46.93 |
100% |
46.93 |
не се прилага на лица под 18 години |
J44.8,J45.0,J45.1 |
НСР-4736/02.10.2014; НСР-11067/01.12.2016; НСР-15149/02.03.2018; НСР-18991/13.06.2019 |
02.08.2019 |
|
|
Активен |
4017 |